Form 4: Relmada Therapeutics Officer Chuck Ence Reports Stock Option Transactions

Chuck Ence, an officer at Relmada Therapeutics, reported acquiring and forfeiting stock options related to the company's 2021 Equity Incentive Plan.

Summary

• On May 24, 2024, Chuck Ence, an officer of Relmada Therapeutics, reported transactions involving stock options.
• Ence became entitled to receive options for 54,624 additional shares of common stock under the company's 2021 Equity Incentive Plan.
• These additional shares became available due to expirations, cancellations, forfeitures, and terminations of other outstanding awards.
• Simultaneously, Ence voluntarily forfeited a portion of his existing stock options, also equal to 54,624 shares.
• The forfeited shares will be allocated to holders of similar awards who are not executive officers or directors of the Issuer.
• Following these transactions, Ence directly owns 136,714 stock options with an exercise price of $2.48 and 82,090 stock options with an exercise price of $2.48.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock option transactions. It doesn't inherently convey positive or negative sentiment.

Positives

• The forfeiture of options by an officer to benefit other employees could be seen as a positive gesture.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The reallocation of forfeited options could have a minor positive impact on the employees who receive them.

Key Dates

Keywords

stock options, Relmada Therapeutics, Form 4, beneficial ownership, equity incentive plan, RLMD, Chuck Ence